Prevail Therapeutics Inc. PRVL
We take great care to ensure that the data presented and summarized in this overview for Prevail Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PRVL
Top Purchases
Top Sells
About PRVL
Insider Transactions at PRVL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 22
2021
|
Peter A. Thompson Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
13,822,463
-100.0%
|
-
|
|
Jan 22
2021
|
Carl L Gordon Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
13,822,463
-100.0%
|
-
|
|
Jan 22
2021
|
Ran Nussbaum Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
1,576,881
-100.0%
|
-
|
|
Jan 22
2021
|
Francois Nader Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
23,747
-100.0%
|
-
|
|
Jan 22
2021
|
Emily Minkow Chief Business Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
13,000
-100.0%
|
-
|
|
Jan 22
2021
|
Asa Abeliovich President & CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
2,385,756
-100.0%
|
-
|
|
Jan 22
2021
|
Orbimed Advisors LLC Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
13,822,463
-100.0%
|
-
|
|
Jan 22
2021
|
Tyto Acquisition Corp > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
34,284,789
+100.0%
|
$754,265,358
$22.5 P/Share
|
|
Dec 30
2020
|
Asa Abeliovich President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
89,037
-3.6%
|
$2,047,851
$23.02 P/Share
|
|
Dec 30
2020
|
Asa Abeliovich President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
125,793
+2.43%
|
$628,965
$5.22 P/Share
|
|
Jun 24
2019
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
882,352
+6.0%
|
$14,999,984
$17.0 P/Share
|
|
Jun 24
2019
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
10,510,111
+44.82%
|
-
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders